Daiichi Sankyo enrols first patient in Phase III acute myeloid leukaemia trial
Daiichi Sankyo has enrolled their first patient in the global phase 3 QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients with newly-diagnosed FLT3-ITD-positive (+) acute myeloid leukaemia (AML).
Click on this link for more information.
